Research Topics
| John M RobertsonSummaryAffiliation: William Beaumont Hospital Country: USA Publications
| Collaborators
|
Detail Information
Publications
Phase I study of conformal radiotherapy and concurrent full-dose gemcitabine with erlotinib for unresected pancreatic cancerJohn M Robertson
Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI 48073, USA
Int J Radiat Oncol Biol Phys 82:e187-92. 2012..To determine the recommended dose of radiotherapy when combined with full-dose gemcitabine and erlotinib for unresected pancreas cancer...- Predicting grade 3 acute diarrhea during radiation therapy for rectal cancer using a cutoff-dose logistic regression normal tissue complication probability modelJohn M Robertson
William Beaumont Hospital, Department of Radiation Oncology, Royal Oak, Michigan 48073, USA
Int J Radiat Oncol Biol Phys 77:66-72. 2010..Understanding the dose-volume relationship of small bowel irradiation and severe acute diarrhea may help reduce the incidence of this side effect during adjuvant treatment for rectal cancer... 
The dose-volume relationship of small bowel irradiation and acute grade 3 diarrhea during chemoradiotherapy for rectal cancerJohn M Robertson
Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI 48073, USA
Int J Radiat Oncol Biol Phys 70:413-8. 2008..This study tested the previously defined parameters in a much larger group of patients...- The role of radiation therapy for colorectal cancerJohn M Robertson
Department of Radiation Oncology, William Beaumont Hospital, 3601 West Thirteen Mile Road, Royal Oak, MI 48073, USA
Gastroenterol Clin North Am 37:269-85, ix. 2008..This article reviews these trials to illustrate key concepts, places these trials in perspective, and provides direction for future research... - Generic planning target margin for rectal cancer treatment setup variationJohn M Robertson
Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI 48073, USA
Int J Radiat Oncol Biol Phys 74:1470-5. 2009..To calculate the generic planning target margin (GPTM) for patients receiving radiation therapy (RT) for rectal cancer placed in a prone position with a customized cradle for small-bowel exclusion... - Dose-volume analysis of predictors for gastrointestinal toxicity after concurrent full-dose gemcitabine and radiotherapy for locally advanced pancreatic adenocarcinomaJiayi Huang
Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI, USA
Int J Radiat Oncol Biol Phys 83:1120-5. 2012..To identify dosimetric predictors for the development of gastrointestinal (GI) toxicity in patients with locally advanced pancreatic adenocarcinoma (LAPC) treated with concurrent full-dose gemcitabine and radiotherapy (GemRT)... - Long-term results of full-dose gemcitabine with radiation therapy compared to 5-fluorouracil with radiation therapy for locally advanced pancreas cancerJiayi Huang
Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, USA
Radiother Oncol 99:114-9. 2011..To retrospectively compare the efficacy and toxicity of full-dose gemcitabine based chemoradiotherapy (GemRT) versus 5-fluorouracil (5-FU) based chemoradiotherapy (5FURT) for locally advanced pancreas cancer (LAPC)... - The influence of small bowel motion on both a conventional three-field and intensity modulated radiation therapy (IMRT) for rectal cancerJoost J Nuyttens
Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI, USA
Cancer Radiother 8:297-304. 2004.... - The dose-volume relationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancerKathy L Baglan
Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI 48073, USA
Int J Radiat Oncol Biol Phys 52:176-83. 2002..CONCLUSIONS: A strong dose-volume relationship exists for the development of Grade 3+ acute small bowel toxicity in patients receiving concurrent 5-FU-based chemoradiotherapy for rectal carcinoma... - Survival after chemoradiation in resected pancreatic cancer: the impact of adjuvant gemcitabineAndrew Baschnagel
Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, Michigan 48072, USA
Int J Radiat Oncol Biol Phys 83:e331-5. 2012..To evaluate survival in patients with resected pancreatic cancer treated with concurrent chemoradiation with or without adjuvant gemcitabine (Gem)... - Adjuvant therapy in pancreatic cancer: Phase I trial of radiation dose escalation with concurrent full-dose gemcitabineAaron M Allen
Department of Radiation Oncology, University of Michigan School of Medicine, 1500 E. Medical Center Drive, Ann Arbor, MI 48109-0010, USA
Int J Radiat Oncol Biol Phys 59:1461-7. 2004..In this high-risk population, data on locoregional control suggest that the reduction in radiation dose and field size minimizes toxicity and does not result in excess failures at these sites... - The variability of the clinical target volume for rectal cancer due to internal organ motion during adjuvant treatmentJoost J Nuyttens
Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI, USA
Int J Radiat Oncol Biol Phys 53:497-503. 2002..5 cm. Other borders of the CTV were based on muscle, bone, or major blood vessels and were stable. CONCLUSION: Modification of the CTV to design a PTV can be unequal, with the largest change at the anterior border of the inferior pelvis... - Sorafenib and radiation: a promising combination in colorectal cancerAndrew W Suen
Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI, USA
Int J Radiat Oncol Biol Phys 78:213-20. 2010..To examine the combination of radiation and the multikinase inhibitor sorafenib in human colorectal cancer cell lines and xenografts... - MicroPET/CT imaging of an orthotopic model of human glioblastoma multiforme and evaluation of pulsed low-dose irradiationSean S Park
Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, Michigan 48073, USA
Int J Radiat Oncol Biol Phys 80:885-92. 2011.... - Stereotactic radiotherapy reduces treatment cost while improving overall survival and local control over standard fractionated radiation therapy for medically inoperable non-small-cell lung cancerThomas B Lanni
Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI 48072, USA
Am J Clin Oncol 34:494-8. 2011..We compare treatment outcomes and costs between SBRT and EBRT in this patient population... - Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144Stephen R Smalley
Kansas City Community Clinical Oncology Program (CCOP, Kansas City, KS, USA
J Clin Oncol 24:3542-7. 2006..LRF with postoperative therapy is low, justifying initial resection for T1-2, N0-2 and T3, and N0-2 anterior resection candidates...